Zika and dengue combined vaccine - Excivion/Xenetic Biosciences
Latest Information Update: 28 Sep 2020
At a glance
- Originator Excivion; Xenetic Biosciences
- Developer Xenetic Biosciences
- Class Dengue vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dengue; Zika virus infection
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Dengue in United Kingdom (Parenteral)
- 28 Sep 2020 No recent reports of development identified for research development in Zika-virus-infection in United Kingdom (Parenteral)
- 18 Aug 2016 Xenetic Biosciences and Excivion collaborate to co-develop Zika and dengue vaccine in United Kingdom
Development Overview
Introduction
Xenetic Biosciences and Excivion are developing vaccines against zika and dengue viruses, using IMUXEN™ technology. IMUXEN™ technology of Xenetic Biosciences is a vaccine delivery platform provides simultaneously a prime and boost effect with a single shot of vaccine that stimulates strong and long-lasting immune responses. It also enhances the potency of vaccine antigens and provides for cold-chain-free distribution and stockpiling of vaccines for pandemic emergencies. Development of the vaccine is in early research stage in the UK.
As at September 2020, no recent reports of development had been identified for research development in Dengue in United Kingdom (Parenteral), research development in Zika-virus-infection in United Kingdom (Parenteral).
Company Agreements
In August 2016, Xenetic Biosciences and Excivion entered into an agreement to develop combined vaccine against zika and dengue viruses [1] .
Key Development Milestones
Financing information
The development of a vaccine against zika and dengue viruses is funded by Innovate UK, under the Small Business Research Initiative (SBRI) contract from the innovation agency of the UK [1] .
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Dengue vaccines, Zika virus vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07B-X (Other viral vaccines)
-
EPhMRA code
J7E9 (All other viral vaccines)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Dengue | - | - | No development reported (Research) | United Kingdom | Parenteral / unspecified | Xenetic Biosciences | 28 Sep 2020 |
| Zika virus infection | - | - | No development reported (Research) | United Kingdom | Parenteral / unspecified | Xenetic Biosciences | 28 Sep 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Xenetic Biosciences | Originator | England |
| Excivion | Originator | United-Kingdom |
| Xenetic Biosciences | Owner | England |
| Excivion | Owner | United-Kingdom |
| Innovate UK | Funder | United-Kingdom |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Sep 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Dengue in United Kingdom (Parenteral) Updated 28 Sep 2020 |
| 28 Sep 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Zika-virus-infection in United Kingdom (Parenteral) Updated 28 Sep 2020 |
| 18 Aug 2016 | Licensing Status | Xenetic Biosciences and Excivion collaborate to co-develop Zika and dengue vaccine in United Kingdom [1] Updated 02 Sep 2016 |
| 18 Aug 2016 | Phase Change | Early research in Dengue in United Kingdom (Parenteral) [1] Updated 02 Sep 2016 |
| 18 Aug 2016 | Phase Change | Early research in Zika virus infection in United Kingdom (Parenteral) [1] Updated 02 Sep 2016 |
References
-
Xenetic Biosciences Announces Collaboration with Excivion Ltd., UK, to Develop a Novel Combined Zika and Dengue Vaccine.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG